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Using Murine Models to investigate 
Tumor–Lymphoid interactions: 
Spotlight on Chronic Lymphocytic 
Leukemia and Angioimmunoblastic 
T-Cell Lymphoma
Tyler A. Herek and Christine E. Cutucache*
Department of Biology, University of Nebraska at Omaha, Omaha, NE, USA
The role of the tumor microenvironment in leukemias and lymphomas is well established, 
yet the intricacies of how the malignant cells regulate and influence their non-malignant 
counterparts remain elusive. For example, chronic lymphocytic leukemia (CLL) is an 
expansion of malignant CD5+CD19+ B cells, yet the non-malignant T cells play just as 
large of a role in disease presentation and etiology. Herein, we review the dynamic tumor 
cell to lymphoid repertoire interactions found in two non-Hodgkin’s lymphoma subtypes: 
CLL and angioimmunoblastic T-cell lymphoma. We aim to highlight the pivot work done 
in the murine models which recapitulate these diseases and explore the insights that can 
be gained from studying the immuno-oncological regulation of non-malignant lymphoid 
counterparts.
Keywords: lymphoma, chronic lymphocytic leukemia, angioimmunoblastic T-cell lymphoma, immune surveillance, 
tumor-induced immunosuppression
iNTRODUCTiON
The cancer immunosurveillance and immunoediting concepts posit that the immune system plays 
a protective role in tumor development through its ability to recognize and eradicate subclinical 
tumors (1, 2). These theories suggest an ever-shifting balance of tumor eradication and tumor growth 
wherein equilibrium can be lost and tumor growth can be promoted (3, 4). The promotion of tumor 
growth can be viewed as a consequence of the immune system as a function of microenvironmental 
interactions that have been shown to be vital for tumor development and survival (5). Therefore, with 
the immune system playing seemingly two separate, yet opposite, roles within immuno-oncology 
interactions it has garnered the “Janus-faced” moniker (3).
To understand the Janus-faced nature of tumor immunology is to understand the impact that a 
growing tumor has upon its microenvironment; by which we mean how tumors regulate their non-
malignant counterparts. Perhaps it is not surprising the impact a tumor can have on the immune 
system when one considers all the working parts of the immune system function that function in an 
antitumor response (6). From NK cells lysing transformed clones, to presentation of tumor-associated 
antigens by macrophages and dendritic cells to activate T- and therefore B-cells, the immune system 
plays an integral role in producing and expanding tumor-specific responses (3).
Currently, the most effective method of studying the impact of a tumor microenvironment 
(TME) on a host immune system is through the use of murine models (7). Specifically, this would 
extend to transgenic murine models as they allow for the “natural” propagation of a clinical tumor 
within an immunocompetent host; most closely mirroring what is found in humans. In this review, 
FigURe 1 | Summary of tumor–lymphoid interactions in chronic lymphocytic leukemia (CLL) and angioimmunoblastic T-cell lymphoma (AiTL).  
(A) CLL cell–resident T cell interactions exemplified by blockade of T-cell-mediated responses against the CLL cells. (B) AITL cell–resident B cell interactions 
exemplified by stimulation of B cells resulting in hypergammaglobulinemia.
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we summarize and discuss the impact two distinct hemato-
logical malignancies, chronic lymphocytic leukemia (CLL) and 
angioimmunoblastic T-cell lymphoma (AITL), have upon their 
adaptive immunological microenvironmental counterparts (i.e., 
T cells and B cells, respectively) (Figure 1). Explicitly, we sum-
marize how murine models play a role in elucidating the impact 
of a B-cell malignancy (i.e., CLL) on resident T  cells, and the 
impact of a T-cell malignancy (i.e., AITL) on resident B  cells. 
The aforementioned hematological malignancies were chosen as 
representative malignancies to study immuno-oncological inter-
actions due to their intense microenvironmental components. As 
CLL is the most common adult leukemia, we are able rely on a 
wealth of publications and data from both human and murine 
investigations to summarize and discuss the above-mentioned 
interactions. AITL on-the-other-hand is a much rarer and less 
studied disease. Therefore, we will focus on what is currently 
known concerning AITL immuno-oncological interactions and 
put forward recommendations concerning AITL murine models 
and directions for future investigations.
CHRONiC LYMPHOCYTiC LeUKeMiA
Chronic lymphocytic leukemia is the most common adult 
leukemia characterized by the clonal expansion of malignant 
CD5+CD19+ B cells. The clinical presentation of CLL is heteroge-
neous, leading to both an indolent and aggressive form demarcated 
by well-defined prognostic markers (i.e., IGVH status, CD38 and 
ZAP70 expression, and chromosomal aberrations) (8–10).
Chronic lymphocytic leukemia is a malignancy highly depend-
ent on its microenvironment illustrated by the fact that CLL cells 
readily undergo apoptosis in  vitro without coculture of bone 
marrow stromal cells (BMSC) (11–13) or monocyte-derived 
nurse-like cells (NLCs) (13). While both BMSC and NLCs display 
similar recruitment of CLL cells through CXCL12–CXCR4 signal-
ing (12–14), the mechanisms by which these compulsory stromal 
cells engage in cross talk with CLL cells differ. In vitro, CLL cells are 
attracted to BMSC and form a contact-dependent protective niche. 
While in contact with the BMSC, the CLL cells undergo a processes 
termed pseudoemperipolesis, which describes the migration of a 
fraction of the CLL cells beneath the BMSC (14–16). This migra-
tion results in the cross talk and bi-directional activation of both 
the BMSC and CLL cells leading to the upregulation of TCL1 
and FOS/JUN in the CLL cells (17). Conversely, NLC-dependent 
activation of CLL cells is characterized by enhanced CLL cell 
viability through NF-κB activation and the BAFF-/APRIL-binding 
pathways resulting in the expression of the anti-apoptotic protein 
MCL-1 by CLL cells for prolonged survival (18). Additionally, CLL 
cell activation through the B-cell receptor pathway is associated 
with increased secretion of CCL3 and CCL4 chemokines, allowing 
for the enhanced recruitment of accessory cells to the TME (19).
The progressive accumulation of CLL clones is primarily 
attributed to increased apoptotic resistance via exploitation by the 
above-described microenvironments (20); however, proliferative 
centers of CLL have been identified (21). These proliferation cent-
ers, termed pseudo-follicles, are composed of Ki-67+, Survivin+, 
p27−, Bcl-2+, CD23Hi CLL cells and CD40L+ T cells (21–24). As 
a result, CD40 activation and IL-2/IL-10 signaling heighten CLL 
proliferation and upregulate IRF4 (25).
The impact of CLL on T Cells
The T  cells of CLL patients display distinct expression pro-
files (26) and are hallmarked by an exhausted phenotype, 
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attenuated immune synapse formation, decreased cytolitic activity, 
migratory impairments, and dysregulated Rho-GTPase signaling.
T-cell exhaustion is defined by T  cells displaying an over-
expression of inhibitory receptors, decreased effector func-
tion, attenuated cytokine production, and decreased cytolitic 
activity (27). CLL-T  cells have been shown to upregulate the 
surface expression of PD-1, CD160, and CD244, indicative of an 
exhausted phenotype (28). Moreover, these markers are known 
to be highly expressed on effector T cells, indicating a skewing of 
the T-cell compartment of CLL patients to a more mature, effec-
tor differentiation, albeit with attenuated functionality. Further 
support for a skewed T-cell compartment comes from CD4+ 
CLL-T  cells having decreased gene expression of the JNK and 
p38 MAPK pathway activators (MINK, NFRKB, PIK3CB) (26) 
suggesting a defect in Th1 differentiation as the aforementioned 
genes are crucial in the production of IFN-γ (29–31).
The immune synapse is a localization of receptors, costimula-
tory molecules, and adhesive anchors that allows for the engage-
ment and recognition of antigen and activation by T cells (32). 
During the activation process, the cytoskeleton of the T  cell 
undergoes intense rearrangements to better facilitate both con-
tact and signaling through pseudopodia formation and cellular 
polarization. In essence, the T cell grasps the antigen-presenting 
cell (APC) forming what is called the immunological synapse 
(33). Structurally, the immune synapse is described as possessing 
three concentric rings called supramolecular activation clusters 
(SMACs) (34). The central supramolecular activation cluster 
houses the TCR molecules which are relocated from the periph-
ery to be recycled, the peripheral SMAC is vital for maintaining 
adhesion between the cells and is primarily composed of the 
integrin, lymphocyte function-associated antigen 1 (LFA-1), and 
the distal SMAC is a clustering of F-actin. The engagement of 
the components of these SMACs influences the rearrangement of 
the cytoskeleton both by signaling relayed via the TCRs and 
through integrins such as LFA-1. For example, once LAT is phos-
phorylated via Zap70 following T-cell activation the Rho-family 
GTPase exchange factor vav guanine nucleotide exchange factor 1 
(Vav1) is recruited to the synapse (35, 36). Following Vav1 activa-
tion, the small GTPases Ras-related C3 botulinum toxin substrate 
1 (Rac1) and cell division control protein 42 homolog (Cdc42) 
bind GTP and activate actin nucleation promoting factors such 
as Wiskott–Aldrich syndrome protein (WASp) and Wasp-family 
verprolin-homologous protein 2 (WAVE2) which coordinate 
actin-related protein 2/3 (Arp2/3)-dependent polymerization of 
branched actin filaments (37–39). Following actin polymeriza-
tion, the immunological synapse functions as a signal specifier 
acting to focus TCR signaling responses to ensure efficient cross 
talk with the bound APC. Dysregulation of the polymerization 
processes could therefore lead to inefficient effector function 
delivery through poor coordination of T-cell signaling or inef-
fectual delivery of signals to the APC.
Immune synapse formation, including both antigen presen-
tation by CLL cells and the subsequent response by T  cells, is 
attenuated in CLL patients. Phenotypically, immune synapse mal-
formation of CLL-T cells is displayed as a decrease in T-cell–APC 
conjugation and F-actin polymerization, with further decrement 
in T-cell receptor, WASp, Dynamin-2, Lck, Cdc42, and Filamin-A 
recruitment to the synapse site (40, 41). Additionally, the inhibi-
tory receptors CD200R, CD272, and CD279 are upregulated in 
CLL-T  cells, and further impede immune synapse formation 
(28, 42). These aforementioned defects also contribute to 
decreased CD8+ T-cell cytolitic effector function, as granzyme B 
is inefficiently packaged and localized to the immune synapse in 
CLL CD8+ T cells (26, 28).
T cells from CLL patients display migratory defects through 
LFA-1 directed T-cell motility (36). This defect is concurrent with 
the previously described deficiency in cytoskeletal remodeling in 
CLL-T cells (26) and has been determined to be dependent upon 
LFA-1 conformation status. In terms of mRNA expression, there is 
no difference in gene expression of LFA-1 between healthy T cells 
and CLL-T cells. Rather, CLL-T cells showed impaired migration 
due to the inefficiency of the low-affinity conformation of LFA-1 
to bind intercellular adhesion molecule 1 causing an impediment 
in leukocyte rolling, arrest, firm adhesion, and diapedesis (43).
At the center of CLL-mediated T-cell impairments is the 
dysregulation of Rho-GTPase signaling in CLL-T  cells. Rho-
GTPases are members of the Ras superfamily of small GTP-
binding proteins and play key roles in T-cell development, T-cell 
migration, and T-cell differentiation (44). This regulation is 
carried out through Rho-GTPase-mediated cytoskeletal rear-
rangements, as well as signaling through numerous pathways 
(45, 46). After coculture with CLL cells, T cells display lower active 
GTPase signaling for RhoA, Rac1, and Cdc42, as compared with 
coculture of T cells with healthy B cells (42). The dysregulation of 
these signaling molecules is also tied to defective LFA-1-mediated 
migration, where downregulated RhoA, Rac1, and potentiated 
Cdc42 are noted among CLL-T cells. Importantly, Cdc42 levels 
differed in CLL-T  cell migration and stimulation assays and 
suggest that CLL-T  cells do not lose all Rho-GTPase signaling 
potentials; however, they do not display identical signaling pat-
terns as healthy T cells.
evidence from the eμ-TCL1 Model
T-cell impairment is a hallmark feature of CLL and is evident 
within the Eμ-TCL1 murine model. Early investigations into 
the T-cell phenotype in Eμ-TCL1 mice demonstrated decreased 
antigen-specific activation, suppressed mitogen initiated prolif-
eration, and impaired idiotype specific CD8+ T  cell-mediated 
CLL clone lysis (47). Gene expression profiling experiments sup-
ported the phenotypic differences, giving evidence to a dysregu-
lation of the actin-cytoskeleton formation pathways, impaired 
F-actin polymerization, and immune synapse formation (47). 
Additionally, decreased expression of CD28, BTLA, Nfrkb, Pi3k, 
Kfkb, Gadd45b, and Vav3 were observed.
Hofbauer and colleagues (48) were the first to report on the 
immunophenotype of Eμ-TCL1 T-cells, finding an increase 
in the absolute numbers of T  cells in the peripheral blood of 
leukemic mice, with the increased population consisting primar-
ily of CD8+ T cells (~72%). Further, CLL-onset Eμ-TCL1 mice 
experienced a shift between naïve and antigen experience T cells 
(as assessed by CD44 expression), presenting with a 48:48 CD4+ 
naïve:experienced ratio, compared to a 80:20 ratio in wild-type 
control mice. The CD8+ T  cell ratio held a similar shift, with 
an 86:14 naïve:experienced ratio in Eμ-TCL1 mice compared 
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to a 70:27 ratio in wild-type controls (48). Importantly, this 
investigation brought a unique insight into the pathogenesis of 
CLL by establishing the engraftment of CLL spleenocytes within an 
immunocompetent host. This adoptive transfer model decreased 
the latency of CLL onset (83  days post-transfer compared to 
247 days of Eμ-TCL1 development) and fully recapitulated the 
abovementioned skewing of the T-cell compartment. These data 
implicate the transferred CLL clones as being directly responsible 
for the onset of disease progression and changes to the T-cell 
compartment (48).
Recently, extensive work by the Gribben lab sought to delineate 
the mechanism behind the PD-1/PD-L1 signaling axis in T cells 
from Eμ-TCL1 mice, as well as provide important evidence for 
use of PD-L1 checkpoint blockade therapy (49, 50). Importantly, 
these studies lend microenvironmental data to the known role of 
PD-1/PD-L1 signaling in human CLL (49). As CLL developed 
in the Eμ-TCL1 mice, there was a significant correlation in the 
reduction of the percentage of CD3+, CD3+CD4+ T cells, and an 
expansion of CD3+CD8+ T cells in the spleen. This finding is in 
agreement with Hofbauer et al. (48) of a decrease in the CD4+/
CD8+ ratio in Eμ-TCL1 mice for the spleen, peripheral blood, 
and lymph node microenvironments. Further, CD3+CD8+ 
CD44−CD62L+ naïve cells were lost with CLL development, with 
a shift toward CD44+ antigen-experienced T cells in the spleen, 
peripheral blood, lymph node, and bone marrow microenviron-
ments. These antigen-experienced CD44+ T  cells held higher 
proliferation indices, as evidenced by increased Ki-67+ ratios in 
Eμ-TCL1 mice and adoptive transfer recipients (spleenocytes 
transferred into 3-month Eμ-TCL1 mice).
Consistent with aging, both Eμ-TCL1 and wild-type mice 
developed CD3+CD8+PD-1+ T  cells, with higher absolute 
numbers found in Eμ-TCL1 and adoptive transfer mice (49). 
Investigation into the differential function of PD-1+ subsets in 
Eμ-TCL1 mice revealed an enrichment within the PD-1+ popula-
tion for cytotoxic cells (as assessed by CD107a+) with increased 
proliferation ascribed to both PD-1high and PD-1low subsets, with 
the PD-1high population having greater EdU incorporation com-
pared to PD-1low. Finally, immune synapse assays indicated the 
PD-1high population to form smaller synapses when compared to 
the PD-1low population in Eμ-TCL1 T cells, suggesting the PD-1high 
phenotype to contribute more toward T-cell impairment (49).
A causal role for the PD-1/PD-L1 signaling axis impairing 
clone-specific immune responses in Eμ-TCL1 mice has been 
supported by the work of both McClanahan and colleagues (50) 
and Gassner et al. (51). α-PD-L1 blockade administered to Eμ-
TCL1 mice resulted in the effective control of CLL development, 
concurrent with reduction in both spleen sizes and weights (50). 
Treatment of adoptively transferred CLL tumor cells with either 
recombinant PD-1 or anti-CD274 resulted in a significant reduc-
tion of transferred tumor cells at both 2- and 24-h time points 
in peripheral blood (both time points), as well as in the spleen, 
lymph nodes, and lungs (24-h time point) (51). Antibody block-
ade restored the relative median frequencies of CD3+, CD4+, and 
CD8+ T cells, while normalizing the CD4+/CD8+ ratio (50). This 
restoration was observed in conjunction with a reduced shift 
toward the CD44+ phenotype seen in the peripheral blood, bone 
marrow, and spleen.
ANgiOiMMUNOBLASTiC T-CeLL 
LYMPHOMA
Angioimmunoblastic T-cell lymphoma is the second most 
common subtype of mature T-cell lymphoma, known to originate 
by the pathogenic clonal expansion of T-follicular helper (Tfh) 
cells and concordant immune dysfunction (52, 53). AITL is an 
aggressive disease, with a median survival <3 years post-diagnosis 
and 10–30% of patients alive at 5 years post-diagnosis (54, 55). 
The poor prognosis is partially due to the highly dysregulated 
immune system of AITL patients, as most patients succumb to 
infectious complications rather than the disease itself (54, 55).
The changes AITL imparts upon the lymph node microenviron-
ment are considered a consequence of the cellular origins of the 
disease. AITL patients display aberrant lymph node architecture, 
including: hyperplasia of the follicular dendritic meshwork (53), 
proliferation of high-endothelial venules, thickened extra follicular 
meshworks, and neoplastic infiltrate (56). The neoplastic cells can be 
medium sized with round, slightly irregular nuclei featuring abun-
dant clear cytoplasm, with clustering around the high-endothelial 
venules (57, 58). The neoplastic cells themselves may only account 
for 5–30% of the tumor (59), and most of the clinical manifesta-
tions of the disease (i.e., lymphadenopathy, hepatosplenomegaly, 
bone marrow involvement) represent complications arising from a 
compromised immune system (60, 61).
As stated, the cell-of-origin for AITL is the Tfh cell. In healthy 
conditions, these cells are formed from high affinity interactions 
with B cells though a T-cell receptor:antigen-dependent manner 
(62). Tfh cells are located within germinal centers and assist with 
the production of high affinity antibodies by B cells, as well as 
plasma cell differentiation, primarily through secretion of IL-21 
and IL-4 (63, 64). These cells express high levels of ICOS and 
CXCR5 and can be immunophenotypically described as CD4+, 
CD8−, PD-1+, CD10+, BCL6+, and CXCL13+ cells (59, 65, 66). 
As with many mature T-cell lymphomas, AITL cells also exhibit 
defective expression of CD5 and CD7 (65), with further clonal 
aberrations detected in ~90% of cases (58, 67–69). The gene 
signature of AITL is described as very closely related to that 
of Tfh cells, with upregulations of VEGF, PDGFRα, B-cell and 
follicular dendritic cell genes, chemokines, extracellular matrix 
components, and vascular biology-associated genes (70, 71). 
Such findings are in accordance with the changes to the lymph 
node architecture and the common involvement of B  cells in 
AITL disease progression.
The impact of AiTL on B-Cells
Due to a compromised immune system, in conjunction with 
dysregulation of normal immune effector functions, there is a 
high proclivity for developing secondary B-cell malignancies 
among AITL patients (72). These secondary malignancies com-
monly present as either composite lymphomas of diffuse large 
B-cell lymphoma  +  AITL (73, 74) or polyclonal populations 
of immunoblasts or plasma cells (75, 76). The development of 
these secondary malignancies suggests that the malignant T cells 
still hold the effector capacity to stimulate B-cell proliferation 
and antibody production and indicate a relationship between 
the developments of the two separate disease phenotypes 
5Herek and Cutucache Murine Models of Tumor–Lymphoid Interactions
Frontiers in Oncology | www.frontiersin.org May 2017 | Volume 7 | Article 86
(77, 78). Evidence supporting the above hypothesis includes: 
development of hypergammaglobulinemia, gene signature analy-
ses demonstrating an upregulation of genes for B-cell activation 
and/or receptor signaling (CD22, CD20, CD21, CD23, CD24, 
CD37) (79), and histological evaluation of germinal centers 
displaying SH2D1A staining, a protein involved in bi-directional 
activation of T and B cells (80).
Murine Models That Recapitulate the 
Defining Characteristics of AiTL
Unlike the Eμ-TCL1 mice for CLL, there is no current consensus 
murine model for AITL. Currently, three genetic models most 
faithfully recapitulate the defining disease characteristics of AITL 
and how they impact resident B cells will be discussed below.
Tet2gt/gt Model of AITL
The ten–eleven translocation 2 (TET2) gene has been found to 
be mutated in multiple myeloid malignancies (81–83) as well as 
a wide range of AITL and PTCL-NOS cases (84, 85). A loss of 
function mutation in TET2 is associated with aberrant meth-
ylation processes involving the conversion of methylcytosine to 
hydroxymethylcytosine, a common epigenetic marker in cancer 
pathogenesis (86).
While previous studies of Tet2 mutations have been conducted 
(87–89), Muto and colleagues were the first to describe the result-
ant disease in terms of its relation to the development of a T-cell 
lymphoma with follicular helper T-cell-like features (90). After 
backcrossing Tet2 gene trap mice onto the C57BL/6 background 
and aging for 40–60  weeks, Tet2gt/gt mice had no differences in 
complete blood counts or proportions of total T- or B-cell popula-
tions in comparison to wild-type or heterozygous controls. The 
Tet2gt/gt mice presented with splenomegaly and preserved follicle 
structures and an enlargement of germinal centers in some mice. 
Flow cytometry analyses revealed an increase in the absolute #’s 
of T- and B-cell populations, despite harboring no differences 
in the proportions of the overall populations. Further analyses 
displayed an increase in the proportions of Tfh populations in the 
Tet2gt/gt mice, namely: CD4+CD44+PD-1+ and CD4+PD-1+Cxcr5+ 
Tfh cells.
In five of seven mice aged greater than 60 weeks (median age: 
67 weeks), Muto and colleagues (90) observed the development 
of increased splenomegaly, multiple swollen lymph nodes, and 
liver and lung nodules in Tet2gt/gt mice. Histological analysis dem-
onstrated the follicular structures of the spleen to be no longer 
apparent due to the infiltration of large polymorphic cells with 
irregular nuclei and characterized as CD4+PD-1+Cxcr5+ Tfh cells. 
These T cells were determined to be clonal in nature, with distinct 
rearrangements of TCR Vβ/Jβ2. Not observed histologically was 
proliferation of high-endothelial venules, nor eosinophil infiltra-
tion. Then, >60-week mice presented with increased proportions 
of CD4+ T-cell fractions and smaller B220+ B-cell fractions, with 
the T-cell population mostly composed of CD44+PD-1+ cells. Of 
note, there was no difference in serum Ig levels found in Tet2gt/gt 
mice compared to controls.
Consistent with the observation that the malignant cells in 
Tet2gt/gt mice were of Tfh origin, microarray analysis of isolated 
splenic CD4+ T cells from Tet2gt/gt mice compared to control mice 
found the Tet2gt/gt T cells to be enriched for Tfh genes. Notable genes 
found to be highly expressed in the Tet2gt/gt mice include: Bcl6, 
cMaf, PD-1, Icos, and Cxcr5. Control CD4+ T cells were enriched 
for genes involved in Th1/Th2 differentiation by comparison, 
suggesting the downregulation of these genes is necessary for the 
adoption of the Tfh phenotype. Sanger sequencing experiments 
indicated that none of the concurrent mutations identified within 
human AITL (e.g., Flt3, Npm1, Dmnt3a, Idh2, Rhoa) were found 
in the Tet2gt/gt mice. Investigation into the differential methylation 
patterns resulting from reduced Tet2 function revealed disruption 
of the distribution of methylcytosine and hydroxymethylcytosine 
in transcriptional start sites, gene body regions, and CpG islands. 
Specifically, Bcl6 was identified as having aberrant methylation 
suggesting this as a mechanism for increased Bcl6 expansion and 
the induction of the outgrowth of Tfh-like cells (90).
Heterozygous RoquinSan Model of AITL
The sanroquin mouse strain bears a homozygous point mutation 
in the Roquin/Rc3hl gene (91), designated as Roquinsan. This 
point mutation results in increased binding affinity between 
ROQUIN and Icos mRNA resulting in the decreased decay rate 
of the transcript and overall upregulation of gene product (92). 
The upregulation of Icos in these mice results in the expansion 
of Tfh cells driving a disease progression equivocal to a systemic 
lupus-like disease phenotype—a similar phenotype is observed 
in Roquinsan/+ mice but in the absence of systemic autoimmun-
ity (91). However, mice heterozygous for the Roquinsan allele 
(Roquinsan/+) as described in Ellyard et  al. (93) do not develop 
systemic autoimmunity but instead present with asymmetric 
lymphadenopathy. Roquinsan/+ mice had a complete absence 
of generalized lymphadenopathy seen in homozygous mice by 
8 weeks, but instead, 53% developed one to four enlarged lymph 
nodes. The resultant lymphadenopathy was deemed non-lethal 
and caused an increase in the cellularity of the affected lymph 
nodes by 50- to 150-fold. A higher prevalence in females (65%) 
compared to males (41%) was noted for the development of 
the tumor-bearing lymph nodes. Histological examination of 
tumor nodes in Roquinsan/+ mice demonstrated an effacement 
of nodal architecture and vascularization, as well as infiltration 
of small-to-medium sized T cells and large PAX5+ B cells, but no 
expansion of the follicular dendritic cell network. An increase in 
F4/80+ macrophages was observed with prominent vasculariza-
tion and sinusoidal dilation. Reactive B blasts were observed in 
interfollicular areas along with a proliferative and polymorphic 
T-cell infiltrate, small clusters of mature plasma cells, and some 
rosette formation between T cells and large blasts. Tumor lymph 
nodes appeared to have no bearing on un-affected lymph nodes 
in tumor-bearing Roquinsan/+ mice, as un-affected nodes displayed 
typical morphologies with the exception of an increase in mature 
plasma cells found within interfollicular areas. All Roquinsan/+ mice 
presented with increased spleen weight compared to Roquin+/+ 
mice regardless of tumor incidence.
Concurrent with the highly affected lymph node environ-
ment of the Roquinsan/+ mice, increased serum IgG is observed 
consistent with the development of hypergammaglobulinemia 
at 15  weeks of age. While both Roquinsan/+ tumor-bearing and 
non-tumor-bearing mice show a significant increase in IgG 
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production compared to Roquin+/+ mice, tumor-bearing 
Roquinsan/+ mice harbor an additional 1.5-fold increase above 
non-tumor-bearing Roquinsan/+ mice. A finding further corrobo-
rated by flow cytometry analysis revealing an increased B-cell 
fraction in the tumor-bearing lymph nodes of Roquinsan/+ mice 
in comparison to normal lymph nodes from both Roquin+/+ and 
Roquinsan/+ mice. Clonality assessments identified a clonal peak of 
IgH in only 1 of 15 cases, in contrast to clonal arrangements in 12 
of 15 cases for TCR-β.
Swiss Jim Lambert (SJL) Model of AITL
Swiss Jim Lambert mice have been studied extensively as a 
model of lymphoproliferative malignancies. In these mice, 
the germinal center B  cells express an endogenous mouse 
mammary tumor virus (mtv-29) superantigen (vSAg) known 
stimulate and activate CD4+ T cells which in turn drive B cell 
proliferation (94, 95). Through this dual activation paradigm, 
heterogeneous lymphoproliferative disorders develop in >90% 
of mice (96). Recent studies have characterized the heteroge-
neity of SJL lymphomas finding similarities to non-Hodgkin 
lymphomas and moving away from the classical reticulum cell 
sarcoma diagnosis (97, 98).
Jain and colleagues (99) are the first to describe the similari-
ties between RCS and AITL. In an analysis of 80 SJL mice, ~44% 
developed classical SJL disease [i.e., Non-Hodgkin lymphoma 
and/or reticulum cell sarcoma (100)]. In SJL disease-diagnosed 
mice ranging from 2 to 24 months of age, flow cytometry dem-
onstrated an expansion of Tfh cell frequencies (CD4+CXCR5+ 
ICOS+PD-1+) in the spleens of SJL mice compared to C57BL/6 
controls. Additionally, increased frequencies of splenic GC B cells 
(B220+FAS+GL-7+) were also found in SJL mice compared to 
C57BL/6 controls. Microarray analysis of a time course of SJL 
spleens (mice aged 6  weeks, 6  months, 12  months) revealed a 
progressive upregulation of genes involved in Tfh signaling, 
namely: Il21, Il10, Ccl8, and Ccl12. Knockout experiments 
investigating the impact of IL-21-mediated signaling on the SJL 
mice established that Il21r−/− SJL mice showed significant reduc-
tions in frequencies of total CD4+ T cells and Tfh cells in 9.5- to 
12-month mice. A finding concurrent with reduced frequencies 
of GC B cells seen in 3- to 12-month Il21r−/− SJL compared to 
SJL WT controls (99). This finding verifies the IL-21 signaling as 
the etiology of SJL-diseased mice, and re-affirms SJL disease as 
Tfh-based as IL-21 is considered the major effector cytokine for 
Tfh cells (101).
Diagnosed SJL-diseased mice underwent age-related changes 
in splenic and lymph node architecture as assessed by peanut 
agglutinin (PNA) reactivity. Younger mice had well preserved 
follicular structures, but by 12 months had uniformly enlarged 
structures with uneven PNA reactivity. Some mice were noted 
as having highly enlarged follicles that did not contain germinal 
centers. The uncontrolled expansion of these follicles leads to the 
white pulp compressing the red pulp in the spleen.
Higher sera IgG2b protein levels were found in SJL mice 
compared to C57BL/6 controls. Il21r−/− mice exhibited lower 
sera IgG2b sera levels compared to wild-type SJL mice, 
implicating the expanded Tfh cell population as a driver of 
the development of hypergammaglobulinemia. Igh and Tcrb 
genes from spleens of primary lymphoma or SJL-diagnosed 
mice were sequenced to assess the presence or absence of 
clonal populations within the diseased mice. All sequenced 
Tcrb clones contained identical V gene sequences, albeit with 
different J gene sequences. For Igh sequences, high somatic 
hypermutation was evident across all malignant samples with 
overall identities <95%.
CONCLUSiON
The Eμ-TCL1 mouse is a powerful model for CLL with a highly 
analogous microenvironment to that of the human disease (102). 
Reviewed herein, we see the powerful effect a B-cell malignancy 
can have on its T-cell counterparts. In CLL, there is a skewing 
of the T-cell compartment toward antigen-experienced CD8+ 
cytotoxic T cells. These cells further express exhaustion markers 
(e.g., PD-1) that demonstrate their inability to effectively control 
malignant clones. In this scenario, we see that a tumor-specific 
immune response has been stymied by the malignancy itself, 
allowing for continued tumor growth and dissemination. Support 
for this observation is seen in that adoption of the exhausted 
and skewed T-cell phenotype is dependent on the presence of 
CLL clones (48), and α-PD-1 blockade therapies are successful 
in restoring the protective capability of the immune system 
(50, 51). These results demonstrate the potential of treatments 
aimed at restoring immune equilibrium to help combat tumors 
in vivo and give further credence to the necessity and power of 
murine models to support bench-to-bedside investigations.
While there is no current consensus murine model for AITL, 
we have reviewed the three most prominent proposals to-date. 
Of these, both the heterozygous Roquinsan and SJL models 
appear most suited to be used in future studies modeling AITL 
microenvironmental interactions. Importantly, both of these 
models faithfully recapitulate defining disease characteristics 
of AITL, including: Tfh expansion, hypergammaglobulinemia, 
effacement of lymphoid architecture, clonal populations, and 
increased high-endothelial vascularization. It stands to reason 
that future investigations should be aimed not only at additional 
model validations and Tfh-based characterization but also focus 
on the B-cell involvement of AITL that could be key to disease 
pathogenesis.
Taken together, both murine models for CLL and AITL 
effectively recapitulate the in  vivo expansion of key immune 
cells. Studies on CLL that have included both cell types in their 
investigations have provided exceptional clinical insight to 
modulate immune competence and provide treatment for CLL 
(including through immunomodulation therapy). Consequently, 
as seen in CLL, therapies targeted at the lymphoid counterpart 
of AITL (i.e., B  cells) could hold high efficacy and aide in the 
understanding of tumor microenvironmental manipulation of 
resident B cells.
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